Tumor diameter, lymph node metastasis and skin viscosity were the risk factors affecting the expression level of BRCA2, and tumor differentiation was the protective factor (Table 5 and Table 6). This evidence concerns the gene BRCA2 and metastatic malignant neoplasm in the lymph nodes.